MD Anderson Cancer Center And Cellectis Announce A Broad Preclinical And Clinical Strategic Alliance In Cancer Immunotherapy
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS – Nasdaq: CLLS), the gene editing company employing proprietary technologies to develop best-in-class CAR T-cell products in adoptive immunotherapy for cancer, and The University of Texas MD Anderson Cancer Center have entered into a research and development alliance aimed at bringing novel cellular immunotherapies to patients suffering from different types of liquid tumors.
Help employers find you! Check out all the jobs and post your resume.
